Alisha H. Bent, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Meharry Medical College, Nashville, Tennessee, US, MD |
| 2012 | University of Florida, Gainesville, Florida, US, Food Science and Nutrition-Pre-Med, BS |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Clinical Residency, Internal Medicine Resident, University of Texas Southwestern Medical Center, Dallas, Texas |
Board Certifications
| 2022 | American Board of Medical Oncology |
| 2019 | Controlled Substance Registration Certificate |
| 2019 | American Board of Internal Medicine (ABIM) |
Experience & Service
Other Appointments/Responsibilities
Chair, Hematology/Oncology Fellowship Wellness Committee, Houston, TX, 2021 - 2022
Chief Fellow, University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2022
Honors & Awards
| 2021 | Chief Fellow, The University of Texas MD Anderson Cancer Center |
| 2021 | Holmes-Abrams Fellowship Award, Colorectal Cancer Research |
| 2021 | Q&A Panelist, MD Anderson Cancer Center Grand Rounds |
| 2014 | Competitive Academic Scholarship, United Food and Commercial Workers Scholarship |
| 2013 | Competitive Academic Scholarship, George C. and Sarah Hale Scholarship |
| 2013 | Dean's List, Meharry Medical College |
| 2010 | Dean's List, University of Florida |
| 2008 | Presidential Scholar, University of Florida |
Selected Publications
Peer-Reviewed Articles
- Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist 28(12):e1303-e1305, 2023. e-Pub 2023. PMID: 37738316.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
- Kopetz, S, Bent, AH. Going with the Flow. Clinical Cancer Research 27(20), 2021. e-Pub 2021. PMID: 34389607.
- Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clin Genitourin Cancer 17(2):e263-e272, 2019. e-Pub 2019. PMID: 30538068.
- Buran TJ, Sandhu AK, Azeredo AM, Bent AH, Williamson JG, Gu L. Effects of exogenous abscisic acid on fruit quality, antioxidant capacities, and phytochemical contents of southern high bush blueberries. Food Chem 132(3):1375-1381, 2012. e-Pub 2012. PMID: 29243625.
Other Articles
- Bent, AH, Raghavan, S, Dasari, NV, Kopetz, S The Future of ctDNA-Defined Minimal Residual Disease. Clinical colorectal cancer 21(2):89-95, 2022. PMID: 35450837.
- Bent A, Raghavan S, Dasari A, Kopetz S The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022.
Abstracts
- Dasari A, Bent A, Alfaro-Munoz K, Huey R, Johnson B, Lee M, Morelli MP, Morris V, Overman M, Parseghian C, Raghav K, Shen J, Willis J, Newhook T, Uppal A, You Y, Konishi T, Chang G, Kopetz S, Wolff R. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. Journal of Clinical Oncology, 2023. e-Pub 2023.
- Bent, A H, Maru, D M, Vauthey, J, Dasari, A, Johnson, B, Kee, B K, Raghav, K P S. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Bowman, A, Bent, A, Le, T, Christie, A, Wardak, Z, Mickey B, S, Timmerman, R, Hannan, R, Brugarolas, J. Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches. Journal of Clinical Oncology, 2018. e-Pub 2018.
- Bosse, D, Xie, W, Wells, C, Lalani, A, Donskov, F, Bent AH, Sim, H, Beuselinck, B, Bamias, A, Porta, C, Vaishampayan, U, Pal, S, Agarwal, N, Srinivas, S, Rini, B, Alva, A, Wood, L, Kapoor, A, Choueiri, T, Heng C, D. Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). Journal of Clinical Oncology, 2017. e-Pub 2017.
Book Chapters
- Parseghian, C, Bent, AH. Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond, 293-299, 2022.
- Parseghian, C, Bent, A. Colorectal Liver Metastases. In: Targeted Therapy Beyond EGFR and VEGF. Spring Nature, 2021.
Grant & Contract Support
| Date: | 2023 - 2030 |
| Title: | Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation |
| Funding Source: | Cardiff Oncology |
| Role: | PI |
| ID: | 2023-0042 |
| Date: | 2021 - 2024 |
| Title: | DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients with Minimal Residual Disease |
| Funding Source: | UT Md Anderson Cancer Center |
| Role: | Co-PI |
| ID: | 2021-0320 | PID12923 |
| Date: | 2021 - 2022 |
| Title: | Targeting HER3 Expression in Colorectal Cancer |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | PI |
| ID: | FP12027 |
Patient Reviews
CV information above last modified March 03, 2025